CHICAGO – AI has the potential to foster early and accurate disease detection, precision and personalized medicine, population health and care access, clinical decision support, operational efficiencies and improved clinician and patient engagement.
But the reality is, “We are not seeing these…
Source: Healthcareitnews.com and Read More
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
